PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Tilray Brands, Inc. (TLRY.TO)
2.000.05 (2.56%)
1.90 - 2.15
0.48 - 2.54
9.88M / 2.92M (Avg.)
-0.48 | -4.19
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
-3.93%
Negative revenue growth while CRON.TO stands at 5.74%. Joel Greenblatt would look for strategic missteps or cyclical reasons.
-34.20%
Negative gross profit growth while CRON.TO is at 134.34%. Joel Greenblatt would examine cost competitiveness or demand decline.
61.81%
EBIT growth above 1.5x CRON.TO's 23.55%. David Dodd would confirm if core operations or niche positioning yield superior profitability.
61.81%
Operating income growth above 1.5x CRON.TO's 26.29%. David Dodd would confirm if consistent cost or pricing advantages drive this outperformance.
53.38%
Net income growth at 50-75% of CRON.TO's 95.00%. Martin Whitman would question fundamental disadvantages in expenses or demand.
55.11%
EPS growth at 50-75% of CRON.TO's 95.08%. Martin Whitman would suspect a lag in operational efficiency or a higher share count.
55.11%
Diluted EPS growth at 50-75% of CRON.TO's 95.08%. Martin Whitman would question if share issuance or modest net income gains hamper progress.
5.26%
Share count expansion well above CRON.TO's 1.91%. Michael Burry would question if management is raising capital unnecessarily or is over-incentivizing employees with stock.
5.26%
Diluted share count expanding well above CRON.TO's 0.08%. Michael Burry would fear significant dilution to existing owners' stakes.
No Data
No Data available this quarter, please select a different quarter.
-136.34%
Both companies show negative OCF growth. Martin Whitman would analyze broader economic or industry conditions limiting cash flow.
-164.10%
Both companies show negative FCF growth. Martin Whitman would consider an industry-wide capital spending surge or margin compression.
No Data
No Data available this quarter, please select a different quarter.
373.08%
5Y revenue/share CAGR above 1.5x CRON.TO's 199.55%. David Dodd would look for consistent product or market expansions fueling outperformance.
-43.99%
Negative 3Y CAGR while CRON.TO stands at 90.83%. Joel Greenblatt would look for missteps or fading competitiveness that hurt sales.
-41900.71%
Negative 10Y OCF/share CAGR while CRON.TO stands at 71.74%. Joel Greenblatt would scrutinize managerial effectiveness and product competitiveness.
60.67%
5Y OCF/share CAGR at 50-75% of CRON.TO's 90.82%. Martin Whitman would question if the firm lags in monetizing revenue effectively.
89.54%
3Y OCF/share CAGR similar to CRON.TO's 95.44%. Walter Schloss might see both benefiting from a rising tide or parallel expansions.
-3781.62%
Negative 10Y net income/share CAGR while CRON.TO is at 65.79%. Joel Greenblatt sees a major red flag in long-term profit erosion.
-193.75%
Both exhibit negative net income/share growth over five years. Martin Whitman would suspect a challenging environment for the entire niche.
-402.19%
Negative 3Y CAGR while CRON.TO is 98.68%. Joel Greenblatt might call for a short-term turnaround strategy or cost realignment.
5906.98%
10Y equity/share CAGR above 1.5x CRON.TO's 1364.12%. David Dodd would confirm if consistent earnings retention or fewer write-downs drive this advantage.
-16.70%
Both show negative equity/share growth mid-term. Martin Whitman suspects cyclical or structural challenges for each company.
-14.43%
Both show negative short-term equity/share CAGR. Martin Whitman suspects an industry slump or unprofitable expansions for both players.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-4.81%
Both reduce receivables yoy. Martin Whitman suspects a shift in the entire niche’s credit approach or softer demand.
15.72%
Inventory growth well above CRON.TO's 0.47%. Michael Burry suspects overshooting production or weaker sell-through vs. the competitor.
2.21%
Positive asset growth while CRON.TO is shrinking. John Neff sees potential for us to outgrow the competitor if returns are solid.
-2.95%
Both erode book value/share. Martin Whitman suspects a difficult environment or poor capital deployment for both players.
-4.65%
Both reduce debt yoy. Martin Whitman sees a broader sector shift to safer balance sheets or less growth impetus.
-56.11%
Both reduce R&D yoy. Martin Whitman sees an industry shifting to cost reduction or limited breakthroughs in the near term.
-13.48%
Both reduce SG&A yoy. Martin Whitman sees a cost war or cyclical slowdown forcing overhead cuts.